Serum Apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with fev1 in atopic asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 9, 2015, Pages 990-1000

  Barochia, Amisha V ^a   Kaler, Maryann ^a   Cuento, Rosemarie A ^a   Gordon, Elizabeth M ^a   Weir, Nargues A ^a   Sampson, Maureen ^b   Fontana, Joseph R ^a   MacDonald, Sandra ^a   Moss, Joel ^a   Manganiello, Vincent ^a   Remaley, Alan T ^a   Levine, Stewart J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Airflow obstruction; Apolipoproteins; Asthma; Lipids; Lipoprotein particles

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ASTHMA; BLOOD; COMPARATIVE STUDY; COMPLICATION; CONTROLLED CLINICAL TRIAL; IMMEDIATE TYPE HYPERSENSITIVITY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AIRWAY OBSTRUCTION; APOLIPOPROTEIN A-I; ASTHMA; CHOLESTEROL, HDL; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MALE; MIDDLE AGED;

EID: 84929001205     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201411-1990OC     Document Type: Article

References (50)

1. Ridker PM. LDL cholesterol: controversies and future therapeutic directions. Lancet 2014;384:607-617.
2. Lüscher TF, Landmesser U, von Eckardstein A, Fogelman AM. Highdensity lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 2014;114:171-182.
3. Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet 2014; 384:618-625.
4. Draper DW, Madenspacher JH, Dixon D, King DH, Remaley AT, Fessler MB. ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. Am J Respir Crit Care Med 2010;182: 404-412.
5. Goldklang M, Golovatch P, Zelonina T, Trischler J, Rabinowitz D, Lemaître V, D'Armiento J. Activation of the TLR4 signaling pathway and abnormal cholesterol efflux lead to emphysema in ApoE-deficient mice. Am J Physiol Lung Cell Mol Physiol 2012;302:L1200-L1208.
6. Gowdy KM, Fessler MB. Emerging roles for cholesterol and lipoproteins in lung disease. Pulm Pharmacol Ther 2013;26:430-437.
7. Martens GW, Arikan MC, Lee J, Ren F, Vallerskog T, Kornfeld H. Hypercholesterolemia impairs immunity to tuberculosis. Infect Immun 2008;76:3464-3472.
8. Massaro D, Massaro GD. Developmental alveologenesis: new roles for ApoE and LDL receptor. Pediatr Res 2011;70:458-461.
9. Samokhin AO, Bühling F, Theissig F, Brömme D. ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis. Am J Pathol 2010;176:1148-1156.
10. Thomassen MJ, Barna BP, Malur AG, Bonfield TL, Farver CF, Malur A, Dalrymple H, Kavuru MS, Febbraio M. ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis. J Lipid Res 2007;48:2762-2768.
11. Wang W, Xu H, Shi Y, Nandedkar S, Zhang H, Gao H, Feroah T, Weihrauch D, Schulte ML, Jones DW, et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res 2010; 51:2560-2570.
12. Yamashita CM, Fessler MB, Vasanthamohan L, Lac J, Madenspacher J, McCaig L, Yao L, Wang L, Puntorieri V, Mehta S, et al. Apolipoprotein E-deficient mice are susceptible to the development of acute lung injury. Respiration 2014;87:416-427.
13. Dai C, Yao X, Keeran KJ, Zywicke GJ, Qu X, Yu ZX, Dagur PK, McCoy JP, Remaley AT, Levine SJ. Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-stimulating factor-dependent mechanism. Am J Respir Cell Mol Biol 2012;47:186-195.
14. Park SW, Lee EH, Lee EJ, Kim HJ, Bae DJ, Han S, Kim D, Jang AS, Uh ST, Kim YH, et al. Apolipoprotein A1 potentiates lipoxin A4 synthesis and recovery of allergen-induced disrupted tight junctions in the airway epithelium. Clin Exp Allergy 2013;43:914-927.
15. Nandedkar SD, Weihrauch D, Xu H, Shi Y, Feroah T, Hutchins W, Rickaby DA, Duzgunes N, Hillery CA, Konduri KS, et al. D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J Lipid Res 2011;52:499-508.
16. Yao X, Dai C, Fredriksson K, Dagur PK, McCoy JP, Qu X, Yu ZX, Keeran KJ, Zywicke GJ, Amar MJ, et al. 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol 2011;186:576-583.
17. Dai C, Yao X, Vaisman B, Brenner T, Meyer KS, Gao M, Keeran KJ, Nugent GZ, Qu X, Yu ZX, et al. The ABCA1 transporter attenuates ovalbumin-induced neutrophilic airway inflammation. Am J Respir Cell Mol Biol 2014;51:626-636.
18. Draper DW, Gowdy KM, Madenspacher JH, Wilson RH, Whitehead GS, Nakano H, Pandiri AR, Foley JF, Remaley AT, Cook DN, et al. ATP binding cassette transporter G1 deletion induces IL-17-dependent dysregulation of pulmonary adaptive immunity. J Immunol 2012;188: 5327-5336.
19. Yao X, Fredriksson K, Yu ZX, Xu X, Raghavachari N, Keeran KJ, Zywicke GJ, Kwak M, Amar MJ, Remaley AT, et al. Apolipoprotein E negatively regulates house dust mite-induced asthma via a lowdensity lipoprotein receptor-mediated pathway. Am J Respir Crit Care Med 2010;182:1228-1238.
20. Fessler MB. Next stop for HDL: the lung. Clin Exp Allergy 2012;42: 340-342.
21. Cottrell L, Neal WA, Ice C, Perez MK, Piedimonte G. Metabolic abnormalities in children with asthma. Am J Respir Crit Care Med 2011;183:441-448.
22. National Asthma Education and Prevention Program (National Heart Lung and Blood Institute). Third Expert Panel on the Management of Asthma. Guidelines for the diagnosis and management of asthma: full report 2007. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2010.
23. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-373.
24. Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis 1984;4:225-231.
25. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13: 423-433.
26. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012;125: 1905-1919.
27. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011;8:222-232.
28. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714.
29. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, Buffa J, Kim T, Gerstenecker GS, Gu X, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014;20: 193-203.
30. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57: 392-410.
31. deGoma EM, Rader DJ. High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein? J Am Coll Cardiol 2012;60:517-520.
32. Davidson WS. HDL-C vs HDL-P: how changing one letter could make a difference in understanding the role of high-density lipoprotein in disease. Clin Chem 2014;60:e1-e3.
33. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009;119: 931-939.
34. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384:626-635.
35. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009;29:431-438.
36. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681.
37. Cirillo DJ, Agrawal Y, Cassano PA. Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002;155:842-848.
38. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008; 118:2047-2056.
39. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.
40. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008;300:2142-2152.
41. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-316.
42. Mitchell F. Screening: No need to fast before lipid level tests. Nat Rev Endocrinol 2013;9:65.
43. Enright PL, Ward BJ, Tracy RP, Lasser EC; The Cardiovascular Health Study Research Group. Asthma and its association with cardiovascular disease in the elderly. J Asthma 1996;33:45-53.
44. Erel F, Gulec M, Kartal O, Caliskaner Z, Ozturk S, Yaman H, Kurt Y, Gocgeldic E, Ors F, Karaayvaz M. Serum leptin levels and lipid profiles in patients with allergic rhinitis and mild asthma. Allergol Immunopathol (Madr) 2007;35:232-238.
45. Fenger RV, Gonzalez-Quintela A, Linneberg A, Husemoen LL, Thuesen BH, Aadahl M, Vidal C, Skaaby T, Sainz JC, Calvo E. The relationship of serum triglycerides, serum HDL, and obesity to the risk of wheezing in 85,555 adults. Respir Med 2013;107:816-824.
46. Fessler MB, Massing MW, Spruell B, Jaramillo R, Draper DW, Madenspacher JH, Arbes SJ, Calatroni A, Zeldin DC. Novel relationship of serum cholesterol with asthma and wheeze in the United States. J Allergy Clin Immunol 2009;124:967-974 e961-915.
47. Picado C, Deulofeu R, Lleonart R, Agustí M, Casals E, QuintóL, Mullol J. Lipid and protein metabolism in asthma. Effects of diet and corticosteroid therapy. Allergy 1999;54:569-575.
48. Schäfer T, Ruhdorfer S, Weigl L, Wessner D, Heinrich J, Döring A, Wichmann HE, Ring J. Intake of unsaturated fatty acids and HDL cholesterol levels are associated with manifestations of atopy in adults. Clin Exp Allergy 2003;33:1360-1367.
49. Shenoi A, Kumar L, Sarihyan S, Gangully NK. High density lipoprotein cholesterol and total cholesterol in children with asthma and allergic rhinitis. Acta Paediatr 1992;81:150-152.
50. Yiallouros PK, Savva SC, Kolokotroni O, Behbod B, Zeniou M, Economou M, Chadjigeorgiou C, Kourides YA, Tornaritis MJ, Lamnisos D, et al. Low serum high-density lipoprotein cholesterol in childhood is associated with adolescent asthma. Clin Exp Allergy 2012;42:423-432.